Autolus Therapeutics (NASDAQ:AUTL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a sell rating to a hold rating in a report released on Saturday.

Several other equities research analysts have also recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, July 21st. Wells Fargo & Company lowered their price target on Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $9.12.

Autolus Therapeutics Trading Up 5.6%

Shares of AUTL opened at $1.88 on Friday. The business’s 50 day moving average is $2.31 and its 200 day moving average is $1.89. Autolus Therapeutics has a 12-month low of $1.11 and a 12-month high of $5.00. The company has a market capitalization of $500.34 million, a PE ratio of -2.24 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.06. The business had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $12.92 million. Equities research analysts predict that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AUTL. Bank of America Corp DE grew its position in Autolus Therapeutics by 2,891.7% in the 2nd quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock valued at $2,223,000 after acquiring an additional 942,540 shares during the last quarter. Armistice Capital LLC lifted its holdings in Autolus Therapeutics by 9.1% during the 2nd quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock valued at $27,360,000 after buying an additional 1,000,000 shares in the last quarter. TFG Asset Management GP Ltd boosted its position in Autolus Therapeutics by 10.5% in the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock valued at $21,660,000 after buying an additional 900,000 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Autolus Therapeutics by 41.6% during the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock worth $88,000 after acquiring an additional 11,289 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Autolus Therapeutics during the second quarter valued at approximately $1,288,000. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.